Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 0.99 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 0.99 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 0.99 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 0.99 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 0.99 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 0.99 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 0.99 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 0.99 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 0.99 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 0.99 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 0.99 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 0.99 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 0.99 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 0.99 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.99 |
| ▸ | TACR2 | P21452 | 2/20 | 0.99 |
| ▸ | EGFR | P00533 | 1/20 | 0.99 |
| ▸ | GHRHR | Q02643 | 1/20 | 0.99 |
| ▸ | NPC1 | O15118 | 8/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL7109517 | 1.00 | TUBB4A (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL121908 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL189599 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL14060916 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL301510 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL189598 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL121909 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL1659765 | 0.99 | NPC1 (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL1659767 | 0.99 | NPC1 (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL301509 | 0.99 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283285-B2 | Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it | BBS NANOTECHNOLOGY LTD. (HU) | 2016-03-15 | — | — | US | claimed |
| EP-2978421-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS Nanotechnology Ltd. (HU) | 2016-02-03 | — | — | EP | claimed |
| US-20140294966-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS NANOTECHNOLOGY LLC. (HU) | 2014-10-02 | — | — | US | claimed |
| WO-2014155144-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS NANOTECHNOLOGY LLC (HU) | 2014-10-02 | — | — | WO | claimed |
| EP-1273296-B1 | COMBINATION OF ACETYLDINALINE AND DOCETAXEL | WARNER LAMBERT CO (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030083366-A1 | Combination chemotherapy | GROVE WILLIAM RICHARD (US) | 2003-05-01 | — | — | US | claimed |
| EP-1273296-A2 | Combination chemotherapy | WARNER-LAMBERT COMPANY (US) | 2003-01-08 | — | — | EP | claimed |
| US-9283285-B2 | Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it | BBS NANOTECHNOLOGY LTD. (HU) | 2016-03-15 | — | — | US | disclosed |
| US-9283285-B2 | Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it | BBS NANOTECHNOLOGY LTD. (HU) | 2016-03-15 | — | — | US | disclosed |
| EP-2978421-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS Nanotechnology Ltd. (HU) | 2016-02-03 | — | — | EP | disclosed |
| EP-2978421-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS Nanotechnology Ltd. (HU) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014155144-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS NANOTECHNOLOGY LLC (HU) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014155144-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS NANOTECHNOLOGY LLC (HU) | 2014-10-02 | — | — | WO | disclosed |
| US-20140294966-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS NANOTECHNOLOGY LLC. (HU) | 2014-10-02 | — | — | US | disclosed |
| US-20140294966-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | BBS NANOTECHNOLOGY LLC. (HU) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294966-A1 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, CD63 | TUBB4A 216/4885TUBB 263/4885TUBA3C 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.